Scholar Rock Holding Co. (NASDAQ:SRRK) Shares Bought by Tudor Investment Corp ET AL

Tudor Investment Corp ET AL lifted its holdings in shares of Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) by 124.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 61,895 shares of the company's stock after acquiring an additional 34,262 shares during the quarter. Tudor Investment Corp ET AL owned approximately 0.07% of Scholar Rock worth $2,675,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of SRRK. Barclays PLC grew its holdings in Scholar Rock by 103.4% during the 3rd quarter. Barclays PLC now owns 165,449 shares of the company's stock valued at $1,324,000 after buying an additional 84,118 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Scholar Rock by 1.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 38,726 shares of the company's stock valued at $310,000 after purchasing an additional 379 shares during the last quarter. GAMMA Investing LLC grew its position in shares of Scholar Rock by 51.8% during the 4th quarter. GAMMA Investing LLC now owns 788 shares of the company's stock worth $34,000 after buying an additional 269 shares in the last quarter. Hamilton Lane Advisors LLC acquired a new position in shares of Scholar Rock in the 4th quarter valued at $1,274,000. Finally, Nisa Investment Advisors LLC grew its holdings in Scholar Rock by 1,321.8% in the fourth quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company's stock valued at $48,000 after purchasing an additional 1,031 shares during the period. 91.08% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Scholar Rock news, insider Mo Qatanani sold 68,510 shares of the business's stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $37.40, for a total value of $2,562,274.00. Following the sale, the insider now owns 111,084 shares in the company, valued at $4,154,541.60. The trade was a 38.15 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Edward H. Myles sold 7,809 shares of Scholar Rock stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $36.83, for a total value of $287,605.47. Following the sale, the chief financial officer now owns 140,740 shares of the company's stock, valued at approximately $5,183,454.20. This trade represents a 5.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 255,231 shares of company stock worth $9,220,236. Company insiders own 13.30% of the company's stock.

Analyst Upgrades and Downgrades

Separately, Wedbush reiterated an "outperform" rating and issued a $50.00 price objective on shares of Scholar Rock in a report on Tuesday, March 25th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Scholar Rock has an average rating of "Buy" and a consensus target price of $42.67.

Scholar Rock Stock Down 10.0 %

SRRK stock traded down $3.26 during trading hours on Tuesday, reaching $29.31. 1,998,408 shares of the stock were exchanged, compared to its average volume of 1,263,545. The company has a market cap of $2.78 billion, a price-to-earnings ratio of -12.47 and a beta of 0.37. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.88 and a quick ratio of 3.88. Scholar Rock Holding Co. has a 12 month low of $6.76 and a 12 month high of $46.98. The firm's 50-day moving average is $32.04 and its 200-day moving average is $35.84.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.